RITONAVIR
ANTIVIRAL-HIV BOOSTED PROTEASE INHIBITORS · HIV INFECTION
AHP
Drug class
Pharmacoenhancer - Cytochrome P450 Inhibitors
Pharmacoenhancer cytochrome P450 inhibitors, also known as pharmacokinetic enhancers or "boosting" agents, are drugs specifically administered to inhibit hepatic and intestinal cytochrome P450 enzymes—predominantly the CYP3A subfamily. Read more about Pharmacoenhancer - Cytochrome P450 Inhibitors
20 drugs in this class 11 manufacturers
Drugs in Pharmacoenhancer - Cytochrome P450 Inhibitors
PREZCOBIX PED (darunavir ethanolate/cobicistat)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
JANSSEN PRODUCT
Filter & compare in the drug finder →
Opens the drug finder with Pharmacoenhancer - Cytochrome P450 Inhibitors preselected. Add indication or manufacturer filters there.
Pharmacoenhancer cytochrome P450 inhibitors, also known as pharmacokinetic enhancers or "boosting" agents, are drugs specifically administered to inhibit hepatic and intestinal cytochrome P450 enzymes—predominantly the CYP3A subfamily.
By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing.
Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2.
Because of their potent CYP inhibition, they also carry a high potential for clinically significant drug-drug interactions with other concomitantly administered substrates.
-
okstatemedicalproceedings.com
Pharmacoenhancer cytochrome P450 inhibitors, also known as pharmacokinetic enhancers or "boosting" agents, are drugs specifically administered to inhibit hepatic and intestinal cytochrome P450 enzymes—predominantly the CYP3A subfamily Because of their potent CYP inhibition, they also carry a high potential for clinically significant drug-drug interactions with other concomitantly administered substrates
-
nih.gov
Pharmacoenhancer cytochrome P450 inhibitors, also known as pharmacokinetic enhancers or "boosting" agents, are drugs specifically administered to inhibit hepatic and intestinal cytochrome P450 enzymes—predominantly the CYP3A subfamily
-
fda.gov
By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing
-
nih.gov
By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing
-
fda.gov
By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing
-
nih.gov
Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2
-
hiv.gov
Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2
-
researchgate.net
Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2 Because of their potent CYP inhibition, they also carry a high potential for clinically significant drug-drug interactions with other concomitantly administered substrates
-
fda.gov
Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.